ArticleThe Journal of dermatology2025
Predictors of Dermal Invasion and Sentinel Lymph Node Metastasis in Patients With Extramammary Paget's Disease Without Clinical Lymph Node Enlargement.
Article in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sentinel lymph node biopsy (SLNB) has prognostic value in extramammary Paget's disease (EMPD) without lymph node enlargement; however, its therapeutic value is unknown. The likelihood of sentinel lymph node metastasis is extremely low, especially when the primary tumor is an intraepidermal lesion; therefore, sentinel node biopsy should not be performed in such cases. To avoid excessive sentinel node biopsy in patients with EMPD, we investigated the preoperative biomarkers that predict the degree of invasiveness of the primary tumor and sentinel lymph node metastasis. We reviewed 121 patients who underwent primary resection and SLNB. The invasion level of the primary tumor was intraepidermal in 50 patients (41.3%), microinvasion into the papillary dermis in 34 (28.1%), and deep invasion into/beyond the reticular dermis in 37 (30.6%). The sentinel node metastasis was positive in 0%, 5.9%, and 62.2% of patients in the intraepidermal, microinvasion, and deep invasion groups, respectively. Presence of nodules (odds ratio: 6.820, p = 0.001) and neutrophil-to-lymphocyte ratio (NLR) (≥ 3.03, odds ratio: 4.260, p = 0.009) were identified as independent predictive factors for deep dermal invasion of the primary tumor and sentinel node metastasis (with nodules, odds ratio: 8.460, p < 0.001 and NLR ≥ 2.87, odds ratio: 3.870, p = 0.016). The metastasis-positive group had a significantly lower overall survival than the negative group (median overall survival: 27.6 months vs. not reached, log-rank test, p < 0.001). In conclusion, routine SLNB may be useful for predicting the prognosis of patients with EMPD without clinical lymph node enlargement. However, the likelihood of sentinel lymph node metastasis is extremely low in intraepidermal and microinvasive primary lesions. It may be reasonable to proactively recommend SLNB, particularly in cases with confirmed deep invasion lesions, the presence of nodules, or elevated NLR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.